Why Is JANUX THERAPEUTICS I (JANX) Stock Down Today?
By the Top Tier Newswire AI Desk · November 10, 2026 at 12:02 AM ET · reviewed against 5 wire stories
JANUX THERAPEUTICS I (JANX) is down -27.62% in the latest session. Our newswire has captured 5 stories on JANX across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Janux Therapeutics stock fell 27.62% to close at $12.76 on Monday. The sharp decline followed the company’s announcement of positive initial Phase 1 data for its lead candidate, JANX011, in healthy volunteers. Despite the favorable clinical results, the market reaction was negative, with the stock printing 13 fresh 52-week lows during the session.
What Happened
Janux Therapeutics disclosed preliminary findings from its Phase 1 trial of JANX011 in healthy participants on November 9, 2026. The data provided clinical validation for the company’s ARM platform in autoimmune diseases, supporting the planned development of the drug in patients with the condition. The company outlined its autoimmune development strategy during a discussion of the healthy volunteer data.
Market reaction to the news was mixed. While the data was described as positive, the stock experienced a significant selloff. William Blair characterized the selloff as overdone. Other analysts adjusted their views in response to the data. Truist Securities maintained a Buy rating on the stock and raised its price target to $27. Barclays and Wedbush also updated their price targets for Janux Therapeutics following the announcement.
What The Data Shows
The stock closed at $12.76, near the bottom of its 52-week range, which spans from $12.12 to $35.34. The company has a market capitalization of $1.1 billion and remains unprofitable, with a trailing twelve-month EPS of -1.59. Revenue grew 132.9% over the trailing twelve months, but the net margin stands at -428.7%. The stock exhibits high volatility, with a beta of 2.39. On the day of the announcement, the stock printed 13 fresh 52-week lows, indicating sustained selling pressure throughout the session.
What To Watch
Investors will monitor the company’s next scheduled earnings date for further updates on the JANX011 development timeline. Analyst coverage remains active, with recent price target adjustments from Truist Securities, Barclays, and Wedbush providing a range of valuation perspectives for the stock.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
JANX · Nov 10 session (5-min) · -5.64% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 5 stories · 57/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoSeeking AlphaBULLISH 58Product/PR
Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript
Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM ESTCompany...
On November 09, 2026, Janux Therapeutics Inc (NASDAQ: JANX) announced preliminary findings from its Phase 1 trial of JANX011 in healthy participants and outline
4d agoThe FlyBULLISH 64Analyst
Janux Therapeutics selloff after Phase 1 data ‘overdone,’ says William Blair
4d agoThe FlyBULLISH 61Product/PR
Janux Therapeutics announces initial Phase 1 data for JANX011
4d agoStockTitanBULLISH 64Product/PR
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →